RVX:TSX

Resverlogix Corp.

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. The company's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Resverlogix can be followed on its blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX
RVX:TSX

Expert Comments:

David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm.
read more >
David Kideckel, Beacon Securities Ltd. (11/15/17)
"After taking a deep dive into Canadian biotech, we have concluded that Resverlogix Corp. may be one of the most undervalued biotech companies in Canada. . .we are initiating coverage of the company with a Buy rating and CA$8.55 target price."

John Vandermosten, Zacks Equity Research (8/2/17)
"Resverlogix Corp. began recruiting and dosing participants in the Phase 3 BETonMACE trial of its lead candidate apabetalone (RVX- 208) in high-risk CVD patients with diabetes in November 2015. We believe the trial will take approximately 3 years to complete, targeting topline readout in 2018. . .at the current price, we view Resverlogix shares as undervalued, and in a position to provide long-term upside potential. We maintain our target price to CAD$6.50 per share and believe that expansion into new geographies, the orphan disease program, and renal disease, could provide further upside to our valuation."

Research Driven Investing (7/26/17)
"Resverlogix Corp. is developing apabetalone (RVX-208), a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, Alzheimer's disease, and orphan diseases. . .Resverlogix Corp.'s stock jumped 9.09% Tuesday, to close the day at $1.56. The stock recorded a trading volume of 204,066 shares, which was above its three months average volume of 70,219 shares. . .the share price has gained 39.29% from its 52 week low."

A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential for "3x upside."
read more >
John Vandermosten, Zacks Equity Research (6/14/17)
"Resverlogix Corp. began recruiting and dosing participants in the Phase III BETonMACE trial of its lead candidate apabetalone (RVX- 208) in high-risk CVD patients with diabetes in November 2015. We believe the trial will take approximately 3 years to complete, targeting topline readout in 2018. . .the company announced successful PK study results for its Phase I renal trial and should commence Phase II studies in 1H:17. . .we view Resverlogix shares as undervalued, and in a position to provide long-term upside potential. We increase our target price to CAD$6.50 per share."

Marcel Wijma, Van Leeuwenhoeck Research (5/1/17)
"Resverlogix Corp. is developing small molecules that selectively inhibit Bromodomain and Extra Terminal domain (BET) proteins, a new and emerging target for high risk vascular diseases. The company is the first to test the BET inhibition hypothesis as a new approach for reducing major adverse cardiovascular events (MACE) in high risk diabetes and CKD patients. . .we have increased our valuation based on an estimated higher pricing for apabetalone and expanded markets in high risk CKD patients. . .RVX remains gravely undervalued at the current share price of CAD 1.99. We feel that the company's current total value should be CAD $12.50 per share.

John Vandermosten, Zacks Equity Research (3/30/17)
"Resverlogix Corp.'s lead product candidate, apabetalone, is the first selective BET bromodomain inhibitor in clinical trials for high-risk vascular disease. In the current Phase III BETonMACE trial, apabetalone is targeting a very specific patient population with low HDL, type 2 diabetes mellitus and chronic kidney disease with a high cardiovascular risk for increased MACE. . .our investment thesis for Resverlogix is based on a large and growing underserved market in cardiovascular disease. With a growing older population in the world, and in many cases a less healthy one than in previous generations, the addressable market for therapies that reduce cardiovascular risk is increasing. "

More Expert Comments

Experts Following This Company

David Kideckel, Equity Research- Healthcare & Biotechnology – Beacon Securities Ltd.
John Vandermosten, CFA – Zacks Small-Cap Research
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters, the company and other contributors.

Resverlogix Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Phase III company focused on high-risk CVD population with lead therapeutic - apabetalone
 
Market leader with significant potential – Over 10MM patients in top 7 markets
 
Advancing apabetalone – Phase II CKD trial expected to commence in early 2017